Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials. Zydus, listed as Cadila Healthcare, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero Labs Ltd in signing non-exclusive pacts with Gilead for the drug. The drug, intravenously administered in hospitals, has already been approved for emergency use in severely-ill patients in the United States, India and South Korea.
from Yahoo Finance https://ift.tt/3hlTD6W
Leave a Reply